secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIGAND PHARMACEUTICALS INC (LGND)
CIK:        0000886163
Form:       8-K
Filed at:   2023-12-01T23:59:59+00:00
Accession:  0000886163-23-000092
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Ligand expands Palvella partnership for QTORIN rapamycin; $5M upfront, higher royalty
--------------------------------------------------------------------------------

- Ligand pays $5M upfront; royalty on QTORIN rapamycin raised to 8.0%-9.8% of net sales.
- Palvella's right to reduce royalties eliminated; Ligand gets security interest in royalties and patents.
- Ligand receives option to acquire a single-digit royalty on US sales of any novel QTORIN platform product.
- QTORIN rapamycin Phase 2: 100% of patients (n=12) 'Much/Very Much Improved'; FDA Breakthrough Therapy Nov 2023.
- Phase 3 pivotal trial planned in ~50 patients for Microcystic LMs (no approved treatments, >30,000 US patients).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/886163/000088616323000092/0000886163-23-000092-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/886163/000088616323000092/lgnd-20231129.htm
  HTML page:      https://secwatch.observer/filing/0000886163-23-000092

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer